|
|
|
|
|
by Manuel_D
364 days ago
|
|
The Cass review, most notably, pointed out that the research supporting these claims are extremely weak. In particular there have only been two randomized controlled trials studying blockers in minors, and neither of them saw improvements over the control group. To date, the UK, Finland, Sweden, Italy. Norway, and Denmark have stopped prescribing puberty blockers to minors with gender dysphoria. |
|
Don't get me wrong, trans issues do need more study, but this is also an example of isolated demand for rigor. Why the undue focus and criticism of trans healthcare over treatment of other rare medical conditions, which also tend to lack RCTs?
In addition, trans healthcare in Sweden has historically been behind the US. Trans people were forcibly sterilized up until 2013, and trans healthcare underfunded. In Finland the sterilization was required until 2023!